PharmAust |
High - |
Low - |
Trades - |
Turnover $0 |
Volume 0 |
| 13 November 2026 at 11:42am | ||||
|
Market Cap (13-Nov) $111,926,056 (1,449th) |
Close (30-Jun) $0.075 |
Volume (30-Jun) 0 |
Shortsold (11-Oct) 108,089 (0.02%) (492nd) |
|
52w High $0.000 |
52w Low $0.000 |
P/E - |
EPS -0.02 |
PAA & ONJCRI to Continue MPL Pre-clinical Investigations
PAA released this announcement to the ASX on 5 January 2021, 9:58. The announcement is marked as price sensitive, and is 2 page(s) in length and 400.86kb in size.
You can view all announcements from PAA and see how they appear on a price chart on the announcements page.
At the date of this announcement, PAA was 0.052% short sold according to ASIC data. It was ranked the 449th most shorted stock on the ASX. It remains ranked 492nd as of the latest reported data (11 October 2024).
| Other Recent Announcements from PAA | |
|---|---|
| Results of General Meeting | 30 June 2023, 12:38 |
| Trading Halt | 30 June 2023, 9:48 |
| General Meeting - Chairman Script | 30 June 2023, 9:42 |
| PAA & ONJCRI to Continue MPL Pre-clinical Investigations | 5 January 2021, 9:58 |
| Appendix 2A & s708 notice | 4 January 2021, 8:16 |
| PAA Commences Manufacture of GMP-Grade MPL for Human Trials | 23 December 2020, 8:21 |
| PharmAust to Commence Phase IIb Dog Cancer Trial | 22 December 2020, 8:15 |
If you were already registered, log in here.